AbbVie Inc (ABBV)vsOrthopediatrics Corp (KIDS)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
KIDS
Orthopediatrics Corp
$30.80
+29.30%
HEALTHCARE · Cap: $639.69M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 25377% more annual revenue ($64.39B vs $252.72M). ABBV leads profitability with a 9.8% profit margin vs -15.7%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
KIDS
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Margin of Safety
+71.6%
Fair Value
$60.63
Current Price
$30.80
$29.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Reasonable price relative to book value
15.4% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -11.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : KIDS
The strongest argument for KIDS centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 15.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : KIDS
The primary concerns for KIDS are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while KIDS is a growth play — different risk/reward profiles.
KIDS carries more volatility with a beta of 0.99 — expect wider price swings.
KIDS is growing revenue faster at 15.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 35/100) and 10.2% revenue growth. KIDS offers better value entry with a 71.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Orthopediatrics Corp
HEALTHCARE · MEDICAL DEVICES · USA
OrthoPediatrics Corp. The company is headquartered in Warsaw, Indiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?